Nature子(zi)刊Signal Transduction and Targeted Therapy(IF=38.1) 正式接收(shou)馴鹿生物BCMA CAR-T CT103A(伊基(ji)侖賽注射(she)液(ye))治療(liao)視神經(jing)脊髓炎譜(pu)系疾(ji)病(bing)(NMOSD)IIT臨床試驗I期(qi)研(yan)究中(zhong)期(qi)結果。該研(yan)究是全(quan)球首個CAR-T療(liao)法(fa)在水通道蛋(dan)白(bai)4(AQP4)介導的復發/難治性(xing)(xing)(xing)NMOSD疾(ji)病(bing)領域(yu)的臨床試驗，初步(bu)證明(ming)了BCMA CAR-T療(liao)法(fa)在NMOSD中(zhong)的良好耐(nai)受性(xing)(xing)(xing)和安全(quan)性(xing)(xing)(xing)、持久(jiu)的致病(bing)性(xing)(xing)(xing)抗(kang)體(ti)清(qing)除作用以及潛在的臨床療(liao)效。(醫藥健(jian)聞)